Physician profile
Ani Telimi
NPI 1245701895
$1,588.41
in general payments reported to CMS, 2019-2025
21 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $320 · 2023: $395 · 2024: $349 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $433.10 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $258.00 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $163.61 | 2021-2025 | |
| Shield Therapeutics INC | $156.44 | 2024-2025 | |
| Hologic Sales and Service, LLC | $73.02 | 2021-2025 | Thinprep 2000 Processor, Aptima, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Abbvie INC. | $69.55 | 2021-2022 | |
| Exeltis, USA INC. | $60.12 | 2024-2025 | Slynd |
| Sage Therapeutics, LLC | $53.29 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $39.71 | 2022 | |
| Mayne Pharma Commercial LLC | $39.31 | 2022 | |
| Roche Diagnostics Corporation | $27.88 | 2021 | |
| Supernus Pharmaceuticals, INC. | $27.49 | 2025 | Qelbree |
| Dexcom, INC. | $26.77 | 2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $24.57 | 2025 | |
| Glaxosmithkline, LLC. | $23.31 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $23.27 | 2021 | |
| Convatec INC. | $20.79 | 2025 | |
| Organon LLC | $19.43 | 2022 | |
| Merck Sharp & Dohme LLC | $17.91 | 2021 | |
| Therapeuticsmd, INC. | $17.00 | 2021 | |
| Smith+Nephew, INC. | $13.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ani Telimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.